JPMorgan Raises Eli Lilly's Future Sales Estimates on Strong Mounjaro Growth and New Drug Access, Reaffirms $1,300 Target

JPMorgan has increased its long-term sales forecasts for Eli Lilly, citing explosive international sales of its drug Mounjaro and clearer market access for its new oral weight-loss pill, Foundayo.

The revision was triggered by Lilly's outstanding Q1 2026 results, where Mounjaro's ex-U.S. sales surged over 266%, proving strong global demand and the company's ability to scale.

Future growth is further supported by the recent FDA approval of Foundayo and a new Medicare program starting in July, which will significantly improve patient access and affordability.

JPMorgan has become even more optimistic about Eli Lilly's long-term sales prospects, raising its revenue estimates for 2027 and beyond.

The primary driver behind this confidence is Lilly's stunning first-quarter performance in 2026. While overall sales were strong, the standout figure was the explosive growth of its blockbuster drug, Mounjaro, outside the United States. International sales for the drug surged by an incredible 266.7% compared to the same period last year. This wasn't just a minor outperformance; it was concrete proof that demand for Lilly's GLP-1 treatments is a global phenomenon and that the company is successfully scaling its international operations to meet it.

Adding to this momentum is Lilly's brand-new oral GLP-1 drug, Foundayo. First, it recently gained FDA approval, offering a convenient pill alternative to injections for weight management. Second, and perhaps more importantly, patient access is set to improve dramatically. A new government initiative, the "Medicare GLP-1 Bridge," will launch on July 1, 2026. This program will make Foundayo significantly more affordable for a vast pool of Medicare beneficiaries, creating a clear and predictable catalyst for sales growth in the second half of the year.

Of course, such massive demand raises questions about supply capabilities. Lilly has been proactively addressing this by investing billions of dollars in new manufacturing facilities in places like Wisconsin, Pennsylvania, and China to ensure it can keep up. While a key competitor, Novo Nordisk, has also launched an oral drug, the overall market is expanding so quickly that analysts believe these new options will attract new patients rather than simply cannibalizing sales from existing injectable drugs. It's a classic case of a rising tide lifting all boats.

In short, JPMorgan's updated forecast is a logical reaction to a powerful combination of factors. The validated international success of Mounjaro, a clear market-access path for the promising new drug Foundayo, and a robust manufacturing expansion plan all signal that Lilly's growth narrative has many chapters left, justifying its premium stock valuation.

GLP-1: A class of drugs that mimic a natural hormone to help control blood sugar and reduce appetite, widely used for type 2 diabetes and chronic weight management.
Overweight rating: An analyst's recommendation that a stock is expected to perform better than the average return of other stocks in its sector or the broader market.
P/E (Price-to-Earnings) ratio: A valuation metric that compares a company's current stock price to its earnings per share. A high P/E ratio often suggests that investors expect high future growth.

JPMorgan Raises Eli Lilly's Future Sales Estimates on Strong Mounjaro Growth and New Drug Access, Reaffirms $1,300 Target

JPMorgan has increased its long-term sales forecasts for Eli Lilly, citing explosive international sales of its drug Mounjaro and clearer market access for its new oral weight-loss pill, Foundayo.

The revision was triggered by Lilly's outstanding Q1 2026 results, where Mounjaro's ex-U.S. sales surged over 266%, proving strong global demand and the company's ability to scale.

Future growth is further supported by the recent FDA approval of Foundayo and a new Medicare program starting in July, which will significantly improve patient access and affordability.

JPMorgan has become even more optimistic about Eli Lilly's long-term sales prospects, raising its revenue estimates for 2027 and beyond.

GLP-1: A class of drugs that mimic a natural hormone to help control blood sugar and reduce appetite, widely used for type 2 diabetes and chronic weight management.
Overweight rating: An analyst's recommendation that a stock is expected to perform better than the average return of other stocks in its sector or the broader market.
P/E (Price-to-Earnings) ratio: A valuation metric that compares a company's current stock price to its earnings per share. A high P/E ratio often suggests that investors expect high future growth.